Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a commercial-stage biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies, with an emphasis on oral, once-daily, non-statin treatments for patients with elevated LDL-C who are at risk for cardiovascular disease. This news page aggregates company announcements, clinical updates, partnership developments, and financial disclosures related to Esperion and its products.
Investors and healthcare-focused readers can use this feed to follow Esperion’s progress with NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), including regulatory milestones, commercialization updates, and guideline-related developments. Recent company communications highlight inclusion of bempedoic acid in major cardiovascular guidelines, presentations of new analyses from the CLEAR Outcomes trial, and expansion of access through partners in Europe, Japan, Canada and other regions.
News items also cover Esperion’s pipeline activities, such as the nomination of ESP-2001, a highly specific allosteric ATP-citrate lyase inhibitor for primary sclerosing cholangitis, and broader ACLY-focused research efforts. Financial and corporate updates, including quarterly results, capital raises via public offerings, and executive appointments, are reported through press releases and Form 8-K filings and are reflected in this news stream.
By reviewing the ESPR news feed, readers can see how Esperion describes its Vision 2040 strategy, commercial execution in the U.S. statin-intolerant market, international launches with partners, and ongoing safety and indication communications for NEXLETOL and NEXLIZET. This page offers a centralized view of the company’s publicly released information over time.
Esperion (NASDAQ: ESPR) reported a strong start in Q1 2022, with total revenue of $18.8 million, a 135% increase year-over-year. U.S. product revenue for NEXLETOL and NEXLIZET surged approximately 109% to $13.4 million. Retail prescription equivalents grew 56.7%. The CLEAR Outcomes Trial is nearing 95% MACE accumulation, with expectations for a topline readout in Q1 2023. Despite a net loss of $56.7 million, significantly reduced from $90.9 million in Q1 2021, the company maintains a solid financial outlook with $268.5 million in cash reserves.
Esperion (NASDAQ: ESPR) announced the publication of data from the CLEAR Harmony Open-Label Extension Study on bempedoic acid, demonstrating its long-term safety and efficacy in lowering LDL-C levels over 2.5 years. The study followed 1,462 patients, with results indicating sustained LDL-C reductions of -14.2% for previous bempedoic acid users and -15.0% for those switching from placebo. No new safety concerns emerged, although risks of hyperuricemia and tendon rupture were noted. Bempedoic acid is approved as an adjunct therapy for patients needing additional LDL-C reduction.
Esperion (NASDAQ: ESPR) announced the grant of 48,780 restricted stock units (RSUs) to 14 new employees on April 28, 2022. These RSUs are part of the 2017 Inducement Equity Incentive Plan, aimed at attracting individuals to the company. Each RSU will vest 25% after one year, with the remaining 75% vesting quarterly over three years, contingent on continued employment. This initiative underlines Esperion’s commitment to innovation in cholesterol management, particularly through its oral, once-daily non-statin LDL-cholesterol lowering drugs.
Esperion (NASDAQ: ESPR) has announced that its President and CEO, Sheldon Koenig, will present at the Bank of America Securities 2022 Healthcare Conference on May 10, 2022. The event is set to take place at 3:20 PM PT (6:20 PM ET) and will include both a presentation and individual meetings. Investors can access a live audio webcast through the company's website, with a replay available afterwards for 90 days. Esperion focuses on developing effective oral non-statin medications for cholesterol management, aiming to improve patient health outcomes.
Esperion (NASDAQ: ESPR) has appointed Stephen Rocamboli as a Class I director, filling a vacancy left by Dr. Mark McGovern’s retirement. Rocamboli, who has extensive experience in life sciences, is expected to enhance Esperion’s strategic direction as it commercializes its medicines and prepares for the upcoming CLEAR Outcomes trial readout in Q1 2023. CEO Sheldon Koenig expressed confidence in Rocamboli's contributions towards the commercialization of approved products and the development of new therapies.
Esperion (NASDAQ: ESPR) has announced the launch of the CLEAR ACS trial, aimed at evaluating the efficacy of NEXLIZET in reducing LDL-C in patients post-acute coronary syndrome (ACS). This 24-week study will recruit 500 patients, assessing the drug's safety and effectiveness in diverse, high-risk populations often underrepresented in clinical trials. The findings could significantly impact treatment protocols for LDL-C management. Key endpoints include changes in LDL-C levels and cardiovascular outcomes.
Esperion (NASDAQ: ESPR) plans to report its first-quarter 2022 financial results on May 3, 2022, before U.S. markets open. Following the announcement, management will discuss the results and business progress during a conference call at 8:00 a.m. ET. Interested parties can join the call by dialing (877) 831-3840 or (253) 237-1184, with an access code of 1489326. A live audio webcast will also be available on the Esperion website, along with a replay accessible two hours after the call.
Esperion has released positive pooled Phase 3 data demonstrating significant LDL-C reductions. Bempedoic acid monotherapy resulted in a 26.5% reduction versus placebo, while a fixed-dose combination of bempedoic acid and ezetimibe achieved a 39.2% reduction, both statistically significant (p<0.001). The study involved 427 participants, emphasizing lipid management for statin-intolerant patients. Ongoing trials like CLEAR Outcomes aim to enhance understanding of bempedoic acid’s efficacy. The findings suggest promise for patients unable to tolerate statins, marking a potential shift in cholesterol management strategies.
Esperion presented significant clinical analyses for NEXLETOL (bempedoic acid) at the ACC.22 conference, highlighting its efficacy in lowering LDL-C in patients with renal impairment and hypertension. The analyses, covering over 3,600 patients, demonstrated significant LDL-C reductions (p<0.0001) across various patient groups. NEXLETOL is the first oral, once-daily non-statin LDL-C-lowering medication approved by the FDA in nearly two decades, supporting its use for adults with established cardiovascular disease or heterozygous familial hypercholesterolemia who need additional LDL-C lowering.
Esperion (NASDAQ: ESPR) announced that President and CEO Sheldon Koenig will present at the 21st Annual Needham Healthcare Conference on April 12, 2022. The event will feature a virtual fireside chat and 1:1 meetings, starting at 9:30 a.m. ET. Interested parties can access live audio webcasts on the investor relations section of the Esperion website. Replays will be available for 90 days following the event. Esperion is focused on lipid management, developing innovative medicines to lower cholesterol.
FAQ
What is the current stock price of Esperion Therape (ESPR)?
What is the market cap of Esperion Therape (ESPR)?
